BioMarin Pharmaceutical (BMRN) Expected to Announce Earnings on Wednesday

BioMarin Pharmaceutical (NASDAQ:BMRN) is projected to announce its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.95 per share and revenue of $741.84 million for the quarter. BioMarin Pharmaceutical has set its FY 2025 guidance at 4.200-4.400 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. On average, analysts expect BioMarin Pharmaceutical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

BioMarin Pharmaceutical Trading Up 0.6 %

NASDAQ BMRN opened at $60.02 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The stock’s 50-day simple moving average is $67.02 and its two-hundred day simple moving average is $66.48. BioMarin Pharmaceutical has a twelve month low of $52.93 and a twelve month high of $94.85. The company has a market capitalization of $11.45 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 0.61 and a beta of 0.30.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BMRN. Wedbush reaffirmed an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Scotiabank upped their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a research note on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 9th. Finally, UBS Group raised their price objective on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.00.

Insider Transactions at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the transaction, the chief accounting officer now owns 16,955 shares in the company, valued at $1,212,621.60. The trade was a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.85% of the stock is owned by insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.